Proposal for Cilofexor (GS-9674, Gilead Sciences)

Below is a comprehensive evaluation of cilofexor (GS-9674, Gilead Sciences) as a promising therapeutic candidate for non-alcoholic steatohepatitis (NASH). In the following sections, we review the synthetic origins and chemical class of cilofexor, summarize its therapeutic history including early-phase clinical data and combination trials, describe in detail its mechanism of action at the molecular level, outline the expected biological effects in the context of NASH pathogenesis, and finally provide an overall evaluation that highlights strengths, challenges, and future directions for this candidate.

Overview of Therapeutic Candidate
Cilofexor is a fully synthetic, non-steroidal agonist of the farnesoid X receptor (FXR) that was discovered and subsequently optimized through rational, structure–activity relationship approaches. Early FXR ligands such as GW4064 provided the chemical and conceptual foundation, and cilofexor was further refined by replacing vulnerable motifs such as the stilbene olefin with alternative groups (for example, a cyclopropyl moiety) to enhance aqueous solubility, membrane permeability, and oral bioavailability (Li et al., 2020). This medicinal chemistry breakthrough places cilofexor into a new generation of non-bile acid synthetic FXR agonists that have been developed to address metabolic, inflammatory, and fibrotic disturbances in chronic liver diseases. FXR, a nuclear receptor expressed predominantly in the liver and intestine, regulates bile acid homeostasis, lipid metabolism, and inflammatory responses; thus, molecules belonging to the FXR agonist class have historically been exploited to modulate gene expression for therapeutic benefit in a wide array of metabolic disorders (Hoofnagle, 2020). Compared to steroidal FXR agonists such as obeticholic acid, cilofexor’s non-steroidal structure is designed to reduce off-target adverse effects like severe pruritus and dyslipidemia while maintaining potent receptor activation through an EC₅₀ in the nanomolar range (approximately 37 nM) (Kremoser, 2021). In sum, the synthetic origins and careful molecular optimization of cilofexor clearly demonstrate its intended selectivity and improved pharmacokinetic properties relative to previous FXR ligands, which is central to its development as a candidate for NASH.

Therapeutic History
Over recent years, cilofexor has been thoroughly evaluated in a series of preclinical studies and early-phase clinical trials to establish its safety, tolerability, and target engagement. In an initial Phase 1 clinical trial (ClinicalTrials.gov, 2016), healthy volunteers received escalating doses of cilofexor to evaluate pharmacokinetic and pharmacodynamic parameters, and results showed a dose-dependent increase in circulating fibroblast growth factor 19 (FGF19) and modulation of key biomarkers such as 7α-hydroxy-4-cholesten-3-one (C4) that reflect bile acid synthesis. Subsequent Phase 2 studies conducted in patients with non-alcoholic steatohepatitis have further defined cilofexor’s clinical profile, with trials demonstrating improvements in imaging-based measures of hepatic steatosis (for example, reductions in MRI-proton density fat fraction) as well as favorable shifts in serum markers like ALT, AST, and gamma-glutamyl transferase (ClinicalTrials.gov, 2016). These studies have included both non-cirrhotic individuals and those with early cirrhosis, establishing that cilofexor can be safely administered in populations with progressive liver disease. Moreover, combination studies—such as those in the ATLAS trial (ClinicalTrials.gov, 2018) and other combination protocols where cilofexor was paired with agents like firsocostat (an acetyl-CoA carboxylase inhibitor) or selonsertib (an ASK1 inhibitor)—have demonstrated that cilofexor not only shows measurable monotherapeutic benefits but may also have additive or synergistic effects when targeting de novo lipogenesis or fibrogenic signaling pathways in NASH (ClinicalTrials.gov, 2018; ClinicalTrials.gov, 2019). In these combination settings, cilofexor contributed to further biomarker improvements and modest histological benefits when compared with placebo, thereby reinforcing its potential in the therapeutic landscape of NASH (ClinicalTrials.gov, 2016). Overall, the therapeutic history of cilofexor is characterized by consistent biochemical evidence of FXR engagement and promising early clinical signals in reducing hepatic fat and modulating liver enzymes, which are central to disease management in NASH.

Mechanism of Action
At the molecular level, cilofexor exerts its pharmacological activity by acting as a high-affinity agonist of the farnesoid X receptor (FXR), a bile acid–sensing nuclear receptor intricately involved in maintaining intracellular and systemic metabolic balance. Once cilofexor binds to the ligand-binding domain of FXR, it promotes heterodimerization of FXR with the retinoid X receptor (RXR); this complex then translocates to the nucleus, where it interacts with specific FXR response elements on DNA to modulate the transcription of a diverse range of target genes (Hoofnagle, 2020). One crucial outcome of FXR activation is the induction of fibroblast growth factor 19 (FGF19) in the ileum, which is subsequently secreted into the circulation and acts on the liver to suppress the expression of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid biosynthesis (Hoofnagle, 2020; Ding et al., 2024). This downregulation of CYP7A1 is fundamental to reducing the hepatic bile acid load and thereby preventing cellular injury induced by toxic bile acid accumulation. In addition, FXR activation by cilofexor leads to the upregulation of small heterodimer partner (SHP), a nuclear receptor corepressor that inhibits the activity of sterol regulatory element-binding protein-1c (SREBP-1c), a master regulator of de novo lipogenesis (Dufour et al., 2020). By suppressing SREBP-1c, the expression of lipogenic enzymes, including acetyl-CoA carboxylase (ACC), is diminished; as ACC is responsible for catalyzing the conversion of acetyl-CoA to malonyl-CoA, its downregulation results in decreased levels of malonyl-CoA. Malonyl-CoA is known to inhibit carnitine palmitoyltransferase 1 (CPT1), the enzyme critical for the transport of fatty acids into mitochondria for β-oxidation. Therefore, by lowering malonyl-CoA, cilofexor effectively relieves the inhibition of CPT1, thereby enhancing mitochondrial fatty acid β-oxidation and promoting the oxidation of accumulated lipids within hepatocytes (Dufour et al., 2020; Hoofnagle, 2020).

Beyond these metabolic effects, FXR activation also modulates inflammatory responses; by decreasing bile acid synthesis and improving the bile acid profile, cilofexor indirectly reduces the triggering of inflammatory cascades that are otherwise activated by bile acid overload. Preclinical studies have further demonstrated that FXR agonism results in reduced expression of pro-inflammatory cytokines and amelioration of liver fibrosis, which is supported by histopathological evaluations showing decreased liver stiffness and collagen deposition in treated models (Ding et al., 2024; Drenth & Schattenberg, 2020). Collectively, the mechanism of action of cilofexor is multifaceted; it leverages FXR-mediated transcriptional regulation to alter bile acid synthesis, suppress lipogenesis, and enhance fatty acid oxidation, while concomitantly exerting anti-inflammatory and anti-fibrotic effects. This cascade—from receptor activation to downstream molecular events—provides a strong mechanistic rationale for the use of cilofexor in rebalancing aberrant lipid metabolism and reducing hepatic injury in NASH.

Expected Effect in NASH
The central hypothesis driving the clinical development of cilofexor in NASH is that the targeted activation of FXR will result in beneficial metabolic reprogramming within the liver. By upregulating FGF19, cilofexor is expected to suppress de novo lipogenesis through the downregulation of SREBP-1c and ACC expression. This suppression lowers intracellular malonyl-CoA levels, which in turn relieves the inhibitory effect on CPT1, thereby enhancing mitochondrial β-oxidation of fatty acids (Dufour et al., 2020; Hoofnagle, 2020). The net effect of this molecular cascade is a substantial reduction in hepatic steatosis, addressing one of the defining features of NASH. In clinical settings, early-phase studies with cilofexor have demonstrated measurable reductions in hepatic fat content using imaging technologies such as MRI-PDFF, as well as improvements in liver enzymes (including ALT and AST) that serve as surrogate markers for hepatocellular injury (ClinicalTrials.gov, 2016; Loomba et al., 2021).

Furthermore, cilofexor’s ability to recalibrate bile acid synthesis by downregulating CYP7A1 plays an important modulatory role in reducing bile acid–induced hepatocellular stress and inflammation. When excess bile acids accumulate, they can trigger inflammatory signaling pathways; by normalizing bile acid homeostasis, cilofexor indirectly attenuates inflammation—a key driver of progression from steatosis to fibrosis in NASH (Hoofnagle, 2020; Nathani, 2023). In addition to these effects, observations from clinical trials indicate that cilofexor may decrease fibrosis markers, such as the Enhanced Liver Fibrosis (ELF) score and liver stiffness as measured by transient elastography, suggesting that the compound could also possess anti-fibrotic properties. Taken together, the expected effects in NASH are two-fold: firstly, a direct metabolic benefit from the reduction of hepatic lipid accumulation through enhanced β-oxidation; and secondly, an indirect anti-inflammatory and anti-fibrotic benefit resulting from improved bile acid regulation. The overall result should be an amelioration of the biochemical, structural, and functional disturbances that define NASH pathology.

Overall Evaluation
Considering the mechanistic and clinical evidence obtained from preclinical studies and multiple early-phase trials, cilofexor represents a robust and scientifically grounded candidate for the treatment of NASH. One of its principal strengths is its highly selective, non-steroidal FXR agonist profile, which offers significant advantages over earlier steroidal FXR agonists by reducing common side effects such as pruritus and dyslipidemia when used at optimized doses (Kremoser, 2021; Nathani, 2023). The oral bioavailability and favorable pharmacokinetic profile of cilofexor further support its suitability for chronic administration, a necessary attribute for addressing a progressive, long-term disease like NASH (Li et al., 2020).

Mechanistically, the cascade initiated by FXR activation—comprising FGF19 induction, subsequent CYP7A1 suppression, SHP upregulation, SREBP-1c and ACC inhibition, and ultimately enhanced CPT1-mediated mitochondrial β-oxidation—addresses the core metabolic derangements observed in NASH. This multifaceted mechanism is supported by both biochemical data and imaging studies that document reductions in hepatic steatosis and favorable changes in liver enzyme levels (Hoofnagle, 2020; Dufour et al., 2020). In addition, by normalizing bile acid synthesis and improving the bile acid profile, cilofexor may reduce hepatocyte stress and the inflammatory milieu that drives fibrosis progression—a welcome benefit in a condition where both steatosis and inflammation play central roles (Ding et al., 2024; Drenth & Schattenberg, 2020).

However, challenges remain. Pruritus has been noted as a dose-dependent side effect of FXR agonists, including cilofexor, which necessitates careful dose titration and consideration for long-term tolerability (Loomba et al., 2021). Moreover, while biomarker improvements have been consistently observed, the translation of these surrogate endpoints into sustained histological improvements—particularly fibrosis regression—has been modest in some studies, suggesting that further optimization in dosing strategies or patient selection might be needed (ClinicalTrials.gov, 2016). Additionally, off-target metabolic effects, such as increases in LDL cholesterol and decreases in HDL cholesterol, have been reported and require integrated monitoring during therapy (Nathani, 2023). These considerations underscore the potential need for combination therapies where cilofexor is used alongside agents that can counterbalance lipid perturbations or target complementary pathogenic pathways, such as inhibitors of de novo lipogenesis or anti-inflammatory compounds (Loomba et al., 2021; ClinicalTrials.gov, 2018).

Patient heterogeneity in NASH further complicates the clinical development narrative. The spectrum of NASH ranges from simple steatosis to advanced fibrosis and compensated cirrhosis, and differences in the expression level of FXR and its downstream targets among patients may influence treatment response. Therefore, future clinical trials must incorporate careful stratification of patient subgroups and, if feasible, integrate novel digital pathology or machine learning-based approaches for more accurate quantification of histological endpoints (Loomba et al., 2021; ClinicalTrials.gov, 2021).

In summary, cilofexor’s scientific rationale—grounded in its potent FXR activation, improved pharmacokinetic profile, and demonstrated engagement of key metabolic pathways—combined with promising early clinical signals, positions it as a highly desirable candidate in the evolving treatment landscape for NASH. Continued investment in longer-term studies, optimization of dosing regimens, and potential combination strategies are warranted to fully realize its therapeutic potential. Despite challenges such as pruritus and lipid alterations, the ability of cilofexor to significantly reduce hepatic steatosis, improve liver biochemistry, and possibly attenuate fibrosis supports its further development and inclusion in multidrug regimens designed to address the complex multifactorial pathophysiology of NASH (Hoofnagle, 2020; Loomba et al., 2021; Nathani, 2023).

References
ClinicalTrials.gov. (2016a). Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02654002
ClinicalTrials.gov. (2016b). Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02781584
ClinicalTrials.gov. (2016c). Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02854605
ClinicalTrials.gov. (2018). Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH). Retrieved from https://clinicaltrials.gov/ct2/show/NCT03449446
ClinicalTrials.gov. (2019). Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH). Retrieved from https://clinicaltrials.gov/ct2/show/NCT03987074
ClinicalTrials.gov. (2021). Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH). Retrieved from https://clinicaltrials.gov/ct2/show/NCT04971785

Ding, C., Wang, Z., Dou, X., Yang, Q., Ning, Y., Kao, S., Sang, X., Hao, M., Wang, K., Peng, M., Zhang, S., Han, X., & Cao, G. (2024). Farnesoid X receptor: From structure to function and its pharmacology in liver fibrosis. Aging and Disease. https://doi.org/10.14336/ad.2023.0830

Drenth, J. P. H., & Schattenberg, J. M. (2020). The nonalcoholic steatohepatitis (NASH) drug development graveyard: Established hurdles and planning for future success. Expert Opinion on Investigational Drugs, 29, 1365–1375. https://doi.org/10.1080/13543784.2020.1839888

Dufour, J.-F., Caussy, C., & Loomba, R. (2020). Combination therapy for non-alcoholic steatohepatitis: Rationale, opportunities and challenges. Gut, 69, 1877–1884. https://doi.org/10.1136/gutjnl-2019-319104

Hoofnagle, J. H. (2020). FXR agonists as therapy for liver disease. Hepatology, 72, 1–3. https://doi.org/10.1002/hep.31265

Kremoser, C. (2021). FXR agonists for NASH: How are they different and what difference do they make? Journal of Hepatology, 75, 12–15. https://doi.org/10.1016/j.jhep.2021.03.020

Li, C., Yang, J., Wang, Y., Qi, Y.-T., Yang, W.-q., & Li, Y. (2020). Farnesoid X receptor agonists as therapeutic target for cardiometabolic diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2020.01247

Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., Wapinski, I., Resnick, M., Beck, A. H., Ding, D., Jia, C., Chuang, J.-C., Huss, R. S., Chung, C., Subramanian, G. M., Myers, R. P., Patel, K., Borg, B. B., Ghalib, R., Kabler, H., Poulos, J., Younes, Z., Elkhashab, M., Hassanein, T., Iyer, R., Ruane, P., Shiffman, M. L., Strasser, S., Wong, V. W.-S., & Alkhouri, N. (2021). Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology, 73, 625–643. https://doi.org/10.1002/hep.31622

Nathani, R. R. (2023). Update on clinical trials for nonalcoholic steatohepatitis. Unknown journal.
